Bill Commons

CA AB 554

vetoed

Health care coverage: antiretroviral drugs, drug devices, and drug products.

California · 2025-2026 Regular Session · lower

Quick answers

Did CA AB 554 pass?

No. CA AB 554 passed the legislature but was vetoed on 2026-01-22. Latest recorded action (2026-01-22): Consideration of Governor's veto stricken from file.

What is CA AB 554 about?

Existing law, the Knox-Keene Health Care Service Plan Act of 1975, provides for the licensure and regulation of health care service plans by the Department of Managed Health Care and makes a willful violation of the act a crime. Existing law provides for the regulation of health insurers by the Department of Insurance. Existing law generally prohibits a health care service plan, excluding a Medi-Cal managed care plan, or health insurer from subjecting antiretroviral drugs that are medically necessary for the prevention of HIV/AIDS, including preexposure prophylaxis or postexposure prophylaxis, to prior authorization or step therapy. Under existing law, a health care service plan or health insurer is not required to cover all the therapeutically equivalent versions of those drugs without prior authorization or step therapy if at least one is covered without prior authorization or step therapy. This bill, the Protecting Rights, Expanding Prevention, and Advancing Reimbursement for Equity (PrEPARE) Act of 2025, would instead prohibit a health care service plan, excluding a Medi-Cal managed care plan, or health insurer from subjecting antiretroviral drugs, drug devices, or drug products that are medically necessary for the prevention of HIV/AIDS, to prior authorization or step therapy, but would authorize prior authorization or step therapy if at least one therapeutically equivalent version is covered without prior authorization or step therapy. The bill would specify that, for therapeutically equivalent coverage purposes, a long-acting drug, drug device, or drug product is not therapeutically equivalent to a long-acting drug, drug device, or drug product with a different duration. The bill would require a plan or insurer that covers non-self-administered antiretroviral drugs, drug devices, or drug products that are approved by the United States Food and Drug Administration (FDA) for the prevention of HIV/AIDS as a medical benefit to also include those non-self-administered antiretroviral drugs, drug devices, or drug products as an outpatient prescription drug benefit. This bill would require a nongrandfathered health care service plan contract or health insurance policy to provide coverage for antiretroviral drugs, drug devices, or drug products that are approved by the FDA for HIV preexposure prophylaxis, and would prohibit a nongrandfathered health care service plan contract or health insurance policy from imposing any cost sharing for those drugs, drug devices, or drug products. The bill would prohibit a plan or insurer from imposing cost sharing on a nonformulary antiretroviral drug, drug device, or drug product that is approved by the FDA for HIV preexposure prophylaxis and is covered pursuant to an exception request if the nonformulary antiretroviral drug, drug device, or drug product is therapeutically equivalent to a formulary antiretroviral drug, drug device, or drug product that is approved by the FDA for HIV preexposure prophylaxis and is covered by the plan or insurer without cost sharing. The bill would exempt Medi-Cal managed care plans from these provisions. Because a willful violation of these provisions by a health care service plan would be a crime, this bill would impose a state-mandated local program. The California Constitution requires the state to reimburse local agencies and school districts for certain costs mandated by the state. Statutory provisions establish procedures for making that reimbursement. This bill would provide that no reimbursement is required by this act for a specified reason.

Who sponsors CA AB 554?

Mark González is the primary sponsor of CA AB 554, joined by 5 cosponsors.

Description

Existing law, the Knox-Keene Health Care Service Plan Act of 1975, provides for the licensure and regulation of health care service plans by the Department of Managed Health Care and makes a willful violation of the act a crime. Existing law provides for the regulation of health insurers by the Department of Insurance. Existing law generally prohibits a health care service plan, excluding a Medi-Cal managed care plan, or health insurer from subjecting antiretroviral drugs that are medically necessary for the prevention of HIV/AIDS, including preexposure prophylaxis or postexposure prophylaxis, to prior authorization or step therapy. Under existing law, a health care service plan or health insurer is not required to cover all the therapeutically equivalent versions of those drugs without prior authorization or step therapy if at least one is covered without prior authorization or step therapy. This bill, the Protecting Rights, Expanding Prevention, and Advancing Reimbursement for Equity (PrEPARE) Act of 2025, would instead prohibit a health care service plan, excluding a Medi-Cal managed care plan, or health insurer from subjecting antiretroviral drugs, drug devices, or drug products that are medically necessary for the prevention of HIV/AIDS, to prior authorization or step therapy, but would authorize prior authorization or step therapy if at least one therapeutically equivalent version is covered without prior authorization or step therapy. The bill would specify that, for therapeutically equivalent coverage purposes, a long-acting drug, drug device, or drug product is not therapeutically equivalent to a long-acting drug, drug device, or drug product with a different duration. The bill would require a plan or insurer that covers non-self-administered antiretroviral drugs, drug devices, or drug products that are approved by the United States Food and Drug Administration (FDA) for the prevention of HIV/AIDS as a medical benefit to also include those non-self-administered antiretroviral drugs, drug devices, or drug products as an outpatient prescription drug benefit. This bill would require a nongrandfathered health care service plan contract or health insurance policy to provide coverage for antiretroviral drugs, drug devices, or drug products that are approved by the FDA for HIV preexposure prophylaxis, and would prohibit a nongrandfathered health care service plan contract or health insurance policy from imposing any cost sharing for those drugs, drug devices, or drug products. The bill would prohibit a plan or insurer from imposing cost sharing on a nonformulary antiretroviral drug, drug device, or drug product that is approved by the FDA for HIV preexposure prophylaxis and is covered pursuant to an exception request if the nonformulary antiretroviral drug, drug device, or drug product is therapeutically equivalent to a formulary antiretroviral drug, drug device, or drug product that is approved by the FDA for HIV preexposure prophylaxis and is covered by the plan or insurer without cost sharing. The bill would exempt Medi-Cal managed care plans from these provisions. Because a willful violation of these provisions by a health care service plan would be a crime, this bill would impose a state-mandated local program. The California Constitution requires the state to reimburse local agencies and school districts for certain costs mandated by the state. Statutory provisions establish procedures for making that reimbursement. This bill would provide that no reimbursement is required by this act for a specified reason.

Introduced
2025-03-03
Latest action
2026-01-22 — Consideration of Governor's veto stricken from file.
Bill type
bill
Last updated

Subjects

Sponsors

  • Mark Gonzálezauthor
  • Walliscoauthor
  • Haneyauthor
  • Wienerprincipal coauthor
  • Jacksoncoauthor
  • Wardcoauthor

Committees

Not provided by source.

Action timeline

  1. 2025-02-11

    Read first time. To print.

    reading-1

  2. 2025-02-12

    From printer. May be heard in committee March 14.

  3. 2025-02-24

    Referred to Com. on HEALTH.

    referral-committee

  4. 2025-03-03

    From committee chair, with author's amendments: Amend, and re-refer to Com. on HEALTH. Read second time and amended.

    amendment-introduction,amendment-passage,committee-passage,reading-1,reading-2,referral-committee

  5. 2025-03-04

    Re-referred to Com. on HEALTH.

    referral-committee

  6. 2025-04-30

    From committee: Do pass and re-refer to Com. on APPR. (Ayes 14. Noes 0.) (April 29). Re-referred to Com. on APPR.

    committee-passage,committee-passage-favorable,referral-committee

  7. 2025-05-14

    In committee: Set, first hearing. Referred to suspense file.

    referral-committee

  8. 2025-05-23

    From committee: Amend, and do pass as amended. (Ayes 11. Noes 0.) (May 23).

    amendment-introduction,amendment-passage,committee-passage

  9. 2025-05-23

    Assembly Rule 63 suspended. (Ayes 51. Noes 16. Page 1644.)

  10. 2025-05-23

    Read second time and amended. Ordered returned to second reading.

    amendment-passage,reading-1,reading-2

  11. 2025-05-27

    Read second time. Ordered to third reading.

    reading-1,reading-2,reading-3

  12. 2025-06-03

    Read third time. Passed. Ordered to the Senate. (Ayes 68. Noes 1. Page 2007.)

    passage,reading-1,reading-3

  13. 2025-06-04

    In Senate. Read first time. To Com. on RLS. for assignment.

    reading-1,referral-committee

  14. 2025-06-18

    Referred to Com. on HEALTH.

    referral-committee

  15. 2025-06-24

    From committee chair, with author's amendments: Amend, and re-refer to committee. Read second time, amended, and re-referred to Com. on HEALTH.

    amendment-introduction,amendment-passage,committee-passage,reading-1,reading-2,referral-committee

  16. 2025-07-17

    Read second time and amended. Re-referred to Com. on APPR.

    amendment-passage,reading-1,reading-2,referral-committee

  17. 2025-07-17

    From committee: Amend, and do pass as amended and re-refer to Com. on APPR. (Ayes 9. Noes 0.) (July 16).

    amendment-introduction,amendment-passage,committee-passage,referral-committee

  18. 2025-08-18

    In committee: Referred to suspense file.

    referral-committee

  19. 2025-08-29

    From committee: Do pass. (Ayes 6. Noes 0.) (August 29).

    committee-passage,committee-passage-favorable

  20. 2025-08-29

    Read second time. Ordered to third reading.

    reading-1,reading-2,reading-3

  21. 2025-09-04

    Read third time and amended. Ordered to second reading.

    amendment-passage,reading-1,reading-2,reading-3

  22. 2025-09-08

    Read second time. Ordered to third reading.

    reading-1,reading-2,reading-3

  23. 2025-09-09

    Read third time. Passed. Ordered to the Assembly. (Ayes 31. Noes 0. Page 2664.).

    passage,reading-1,reading-3

  24. 2025-09-09

    In Assembly. Concurrence in Senate amendments pending.

  25. 2025-09-10

    Senate amendments concurred in. To Engrossing and Enrolling. (Ayes 69. Noes 1. Page 3221.).

    amendment-passage,committee-passage,committee-passage-favorable

  26. 2025-09-22

    Enrolled and presented to the Governor at 3 p.m.

    executive-receipt

  27. 2025-10-13

    Vetoed by Governor.

    executive-veto

  28. 2025-10-13

    Consideration of Governor's veto pending.

  29. 2026-01-22

    Consideration of Governor's veto stricken from file.

    veto-override-failure

Versions

  • 02/11/25 - Introduced — 2025-02-11Compare
  • 03/03/25 - Amended Assembly — 2025-03-03Compare
  • 05/23/25 - Amended Assembly — 2025-05-23Compare
  • 06/24/25 - Amended Senate — 2025-06-24Compare
  • 07/17/25 - Amended Senate — 2025-07-17Compare
  • 09/04/25 - Amended Senate — 2025-09-04Compare
  • 09/12/25 - Enrolled — 2025-09-12Compare
  • AB554Compare
  • (document, no version)Compare

Documents

Votes

  • Do pass and be re-referred to the Committee on [Appropriations]

    2025-04-29 · pass · 14-0

    Member-level votes (16)
    • Flora: yes
    • Celeste Rodriguez: yes
    • Mark González: yes
    • Patterson: yes
    • Sharp-Collins: yes
    • Schiavo: yes
    • Bonta: yes
    • Aguiar-Curry: yes
    • Stefani: yes
    • Carrillo: yes
    • Krell: yes
    • Arambula: yes
    • Patel: yes
    • Addis: yes
    • Sanchez: other
    • Chen: other
  • Do pass as amended.

    2025-05-23 · pass · 11-0

    Member-level votes (15)
    • Calderon: yes
    • Elhawary: yes
    • Hart: yes
    • Mark González: yes
    • Arambula: yes
    • Pacheco: yes
    • Solache: yes
    • Caloza: yes
    • Wicks: yes
    • Pellerin: yes
    • Fong: yes
    • Ta: other
    • Sanchez: other
    • Dixon: other
    • Tangipa: other
  • AB 554 Mark González Assembly Third Reading

    2025-06-03 · pass · 68-1

    Member-level votes (79)
    • Berman: yes
    • Jeff Gonzalez: yes
    • Zbur: yes
    • Celeste Rodriguez: yes
    • Gallagher: yes
    • Bonta: yes
    • Blanca Rubio: yes
    • Fong: yes
    • Harabedian: yes
    • Rivas: yes
    • Elhawary: yes
    • Bauer-Kahan: yes
    • Valencia: yes
    • Wilson: yes
    • Wicks: yes
    • Bennett: yes
    • Haney: yes
    • Quirk-Silva: yes
    • Caloza: yes
    • Muratsuchi: yes
    • Soria: yes
    • Schiavo: yes
    • Ávila Farías: yes
    • Gabriel: yes
    • Mark González: yes
    • Nguyen: yes
    • Papan: yes
    • Ransom: yes
    • Bains: yes
    • Addis: yes
    • Kalra: yes
    • Lowenthal: yes
    • Macedo: yes
    • Solache: yes
    • Lee: yes
    • Alanis: yes
    • Ortega: yes
    • Patterson: yes
    • Calderon: yes
    • Patel: yes
    • Ward: yes
    • Hoover: yes
    • Irwin: yes
    • Michelle Rodriguez: yes
    • Krell: yes
    • Pellerin: yes
    • Sharp-Collins: yes
    • Ramos: yes
    • Bryan: yes
    • Boerner: yes
    • Davies: yes
    • Garcia: yes
    • Gipson: yes
    • McKinnor: yes
    • Stefani: yes
    • Connolly: yes
    • Alvarez: yes
    • Petrie-Norris: yes
    • Ahrens: yes
    • Wallis: yes
    • Jackson: yes
    • Schultz: yes
    • Aguiar-Curry: yes
    • Arambula: yes
    • Rogers: yes
    • Pacheco: yes
    • Hart: yes
    • Carrillo: yes
    • DeMaio: no
    • Ta: other
    • Sanchez: other
    • Tangipa: other
    • Ellis: other
    • Hadwick: other
    • Castillo: other
    • Lackey: other
    • Flora: other
    • Chen: other
    • Dixon: other
  • Do pass as amended, but first amend, and re-refer to the Committee on [Appropriations]

    2025-07-16 · pass · 9-0

    Member-level votes (11)
    • Weber Pierson: yes
    • Limón: yes
    • Padilla: yes
    • Rubio: yes
    • Gonzalez: yes
    • Durazo: yes
    • Menjivar: yes
    • Wiener: yes
    • Richardson: yes
    • Valladares: other
    • Grove: other
  • Placed on suspense file

    2025-08-18 · pass · 7-0

    Member-level votes (7)
    • Richardson: yes
    • Seyarto: yes
    • Caballero: yes
    • Cabaldon: yes
    • Dahle: yes
    • Wahab: yes
    • Grayson: yes
  • Do pass

    2025-08-29 · pass · 6-0

    Member-level votes (7)
    • Richardson: yes
    • Grayson: yes
    • Wahab: yes
    • Dahle: yes
    • Caballero: yes
    • Cabaldon: yes
    • Seyarto: other
  • 3rd Reading AB554 Mark González et al. By Cabaldon

    2025-09-09 · pass · 31-0

    Member-level votes (40)
    • Richardson: yes
    • Menjivar: yes
    • Cortese: yes
    • Weber Pierson: yes
    • McNerney: yes
    • Stern: yes
    • Smallwood-Cuevas: yes
    • Becker: yes
    • McGuire: yes
    • Cervantes: yes
    • Hurtado: yes
    • Cabaldon: yes
    • Rubio: yes
    • Durazo: yes
    • Laird: yes
    • Padilla: yes
    • Dahle: yes
    • Limón: yes
    • Pérez: yes
    • Reyes: yes
    • Archuleta: yes
    • Wiener: yes
    • Ashby: yes
    • Arreguín: yes
    • Grayson: yes
    • Allen: yes
    • Gonzalez: yes
    • Caballero: yes
    • Wahab: yes
    • Umberg: yes
    • Blakespear: yes
    • Niello: other
    • Ochoa Bogh: other
    • Grove: other
    • Jones: other
    • Valladares: other
    • Seyarto: other
    • Strickland: other
    • Choi: other
    • Alvarado-Gil: other
  • AB 554 Mark González Concurrence in Senate Amendments

    2025-09-11 · pass · 69-1

    Member-level votes (80)
    • Ahrens: yes
    • Mark González: yes
    • Quirk-Silva: yes
    • Gipson: yes
    • Rogers: yes
    • Addis: yes
    • Ward: yes
    • Haney: yes
    • Hart: yes
    • Fong: yes
    • Calderon: yes
    • Elhawary: yes
    • Wilson: yes
    • Carrillo: yes
    • Bains: yes
    • Ransom: yes
    • Soria: yes
    • Michelle Rodriguez: yes
    • Berman: yes
    • Valencia: yes
    • Wicks: yes
    • Celeste Rodriguez: yes
    • Arambula: yes
    • Connolly: yes
    • Schultz: yes
    • Bauer-Kahan: yes
    • Bennett: yes
    • Papan: yes
    • Schiavo: yes
    • Bonta: yes
    • Ávila Farías: yes
    • Aguiar-Curry: yes
    • Jeff Gonzalez: yes
    • Pacheco: yes
    • Boerner: yes
    • Alvarez: yes
    • Lee: yes
    • Alanis: yes
    • Wallis: yes
    • Patterson: yes
    • Stefani: yes
    • Caloza: yes
    • Hoover: yes
    • Sharp-Collins: yes
    • Nguyen: yes
    • Ortega: yes
    • Solache: yes
    • Lowenthal: yes
    • Blanca Rubio: yes
    • Jackson: yes
    • Bryan: yes
    • Gallagher: yes
    • Petrie-Norris: yes
    • Harabedian: yes
    • Gabriel: yes
    • Ellis: yes
    • Macedo: yes
    • Davies: yes
    • McKinnor: yes
    • Zbur: yes
    • Pellerin: yes
    • Muratsuchi: yes
    • Krell: yes
    • Irwin: yes
    • Ramos: yes
    • Patel: yes
    • Kalra: yes
    • Rivas: yes
    • Garcia: yes
    • DeMaio: no
    • Johnson: other
    • Dixon: other
    • Hadwick: other
    • Tangipa: other
    • Lackey: other
    • Sanchez: other
    • Chen: other
    • Castillo: other
    • Flora: other
    • Ta: other

Related bills

No related bills recorded for this bill.

Official source

Attribution

Data from openstates_bulk_csv, retrieved 2026-07-24T01:34:27.960412Z

Inspect retained evidence for changes recorded after evidence tracking began:

Use this data

Every field on this page is available from the free public API — no key or licence required. Fetch this bill as JSON: GET /api/v1/bills?jurisdiction=CA&identifier=AB 554. See the API docs or the MCP server for AI assistants.

Known limitations

  • Sponsor party and chamber affiliation are not yet captured by this API.
  • Committee referrals are not yet captured.
  • Some documents have no extracted text yet, so version comparison may be limited.

See the methodology page for data sources and limitations.